Thomas Henkel, PhD

CEO & Co-Founder. Targos, Germany

Dr. Thomas Henkel is CEO and co-founder of Targos Molecular Pathology GmbH, Kassel, and serves as acting CEO of the daughter companies Targos Advance AG and Targos Development AG. From 2003 to 2005, he was Head of Biomedical Research at Klinikum Kassel GmbH, an activity leading to the formation of Targos GmbH. Prior to this, Dr. Henkel was Vice President of Research at MediGene AG, Martinsried, which he joined shortly after its inception in 1995, and where he led innovative research programs to commercialisation and through a successful IPO in 2000. From 1993-1995 he worked as a post-doctoral scientist at Tularik Inc, San Francisco, which was acquired by Amgen.

Dr. Henkel received his scientific education and his diploma in Biology and Biochemistry from the Georg-August-Universität and the Max-Planck Institute for Experimental Medicine in Göttingen, Germany. After his graduation he performed scientific work at the Gene Center München, the Hadassah Medical School Jerusalem and the Salk Institute in San Diego. Dr. Henkel holds a PhD in Biochemistry from the Ludwig-Maximilians-Universität München. Dr. Henkel co-authored about 30 publications, including first author papers in Cell, Science, Nature and Annual Reviews in Immunology-one of the most cited and read reviews according to Journal Citation Reports®. He is also author of 15 patent applications. From 2004 Dr. Henkel is a visiting lecturer in Biochemistry at the Universität Kassel.

Management training in München (Germany) and St. Gallen (Switzerland).